● Knockout Mice ● Point Mutation Mice ● Large-fragment Knockin Mice (any locus) ● Large-fragment Knockin Mice (ROSA26) ■ Transgenic services ● Regular Transgenic Mice ● Transgenic Mouse Embryos ● PiggyBac Transgenic Mice ● PiggyBac Transgenic Mouse Embryos ● PiggyBac-on-BAC Transgeni...
Fibroblast growth factor 21 (FGF21) induces weight loss in mouse, monkey, and human studies. In mice, FGF21 is thought to cause weight loss by stimulating thermogenesis, but whether FGF21 increases energy expenditure (EE) in primates is unclear. Here, we explore the transcriptional response and...
Diethynitrosamine (DEN)-induced HCC was done as previously described [41]. In brief, cohorts of male C57BL/6J mice two weeks after birth were injected with DEN intraperitoneally (IP) at 10 mg/Kg body weight. Control mice were injected IP with PBS. Liver tissues from the left lobe were ...
presumablythegenedeletionormutationcanpromotehairfollicledevelopment.CRISPR—Cas9systemisanewgenetarg—tingmodificationtechnologydevelopedfrombacterialacquiredimmunity.Inthisstudy,FGF21globalknockoutmiceweregeneratedbymicroinjectionwithCas9andgRNAplasmid.Depilationexperimentwasmadetocomparethespeedofhairregrowthintwogroups;The...
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14, 385–390 (2005). Google Scholar Modica, S. et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142, 355–365...
展开 关键词: Animals Macaca fascicularis Humans Mice Disease Models, Animal Diabetes Mellitus, Experimental Diabetes Mellitus, Type 2 Fibroblast Growth Factors Recombinant Fusion Proteins Mutation DOI: 10.1371/journal.pone.0049345 被引量: 120 年份: 2012 收藏...
The complementary oligonucleotide harboring the desired mutation contained the sequence AGA instead of CGC at site −69 to −72 and TCT instead of GTC at site −66 to −68 in the FGF21 gene 5′ region (Fig. 5A). Transfection experiments were carried out in the HIB-1B, BAT-derived...
Experimental research provides support for the pharmacological administration of FGF21 for the treatment of type 2 diabetes, obesity, dyslipidemia, and other metabolic conditions or disorders in humans. Human FGF21 has a short half-life in vivo. In mice, the half-life of human FGF21 is 1 to ...
disulfide bond mutationFGF21folding dynamicsNMRFibroblast growth factor 21 (FGF21) is a regulator of glucose and lipid metabolism. It has been widely considered as a promising candidate for the treatment of type 2 diabetes mellitus (T2DM) and other related metabolic disorders. However, lack of ...
The present invention relates, in one aspect, to certain mutant FGF21 polypeptide constructs. In certain non-limiting embodiments, the construct binds to β-Klotho more tightly than wild-type FGF21. In certain non-limiting embodiments, the construct has a mutation in at least one residue of SEQ...